Skip to content
Screener

Spyre Therapeutics, Inc. SYRE Other income, net (Note 6)

Other income, net (Note 6) at other companies

Pfizer logo
PfizerPFE
$3.72B+603%
Johnson & Johnson logo
Johnson & JohnsonJNJ
-$331M-209%
Merck & Co. logo
Merck & Co.MRK
-$99M-1,514%
AbbVie logo
AbbVieABBV
$1.48B+156%
Absci Corporation logo
Absci CorporationABSI
$1.28M-12.0%
Relay Therapeutics, Inc. logo
Relay Therapeutics, Inc.RLAY
$7.12M+10.0%

Other financials

Income statement

See full
Revenue-
Operating income-$45.6M+14.8%
Net income-$69.0M-54.1%
EPS (diluted)-$0.74-23.3%

Balance sheet

See full
Cash & equivalents$97.2M+100%
Total debt$4.3M-9.6%
Total equity$670.8M+39.0%
Total assets$764.0M+34.1%

Cash flow

See full
Operating cash flow-$57.4M-40.0%
CapEx-
Free cash flow-$39.4M-26.8%

Valuation

See full
Market cap$9.12B+846%

Profitability

See full
Operating margin-39,428.9%-49,795pp
Net margin-52,939.7%-61,871pp
FCF margin-3,442.8%-3,807pp

Returns & leverage

See full
Return on equity-31.1%-10.7pp
Debt / equity0.1×+0.1×
Current ratio+0.9×

Where this comes from

Reported directly by Spyre Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OtherNonoperatingIncomeExpense.

The source filing: Spyre Therapeutics, Inc.’s 10-Q, filed May 5, 2026.

Filed
May 5, 2026, 8:00 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001636282-26-000050
Line itemThree Months Ended March 31, 20262025
Loss from operations(45,641)(53,567)
Other (expense) income:
Interest income6,9956,493
Other (expense) income, net(30,359)2,286
Total other (expense) income(23,364)8,779
Loss before income tax expense(69,005)(44,788)
Income tax benefit15
Net loss$(69,005)$(44,773)

Item 1. Financial Statements (Unaudited).

FAQ

What is Spyre Therapeutics, Inc.'s other income, net (note 6)?
Spyre Therapeutics, Inc. (SYRE) reported other income, net (note 6) of -$30.36M in Q1 2026.
How has Spyre Therapeutics, Inc.'s other income, net (note 6) changed year-over-year?
Spyre Therapeutics, Inc.'s other income, net (note 6) decreased by 1428.0% year-over-year, from $2.29M to -$30.36M.
What is the long-term trend for Spyre Therapeutics, Inc.'s other income, net (note 6)?
Over 3 years (2021 to 2024), Spyre Therapeutics, Inc.'s other income, net (note 6) has grown at a 453.7% compound annual growth rate (CAGR), from -$122K to -$20.71M.
What does other income, net (note 6) mean?
This captures miscellaneous financial items that fall outside the scope of core operating activities, such as foreign exchange gains or losses, minor investment income, or non-recurring legal settlements. It serves as a catch-all for peripheral financial events that do not stem from the primary business operations. Investors monitor this to isolate core earnings from transient or incidental financial fluctuations.

Ask your AI about Spyre Therapeutics, Inc.'s other income, net (note 6).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude